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Abstract
Background: p21
WAF1/CIP1 is a well known cyclin-dependent kinase inhibitor induced by various stress stimuli. Depending
on the stress applied, p21 upregulation can either promote apoptosis or prevent against apoptotic injury. The stress-
mediated induction of p21 involves not only its transcriptional activation but also its posttranscriptional regulation, mainly
through stabilization of p21 mRNA levels. We have previously reported that the proteasome inhibitor MG132 induces the
stabilization of p21 mRNA, which correlates with the formation of cytoplasmic RNA stress granules. The mechanism
underlying p21 mRNA stabilization, however, remains unknown.
Methodology/Principal Findings: We identified the stress granules component CUGBP1 as a factor required for p21 mRNA
stabilization following treatment with bortezomib (= PS-341/Velcade). This peptide boronate inhibitor of the 26S
proteasome is very efficient for the treatment of myelomas and other hematological tumors. However, solid tumors are
sometimes refractory to bortezomib treatment. We found that depleting CUGBP1 in cancer cells prevents bortezomib-
mediated p21 upregulation. FISH experiments combined to mRNA stability assays show that this effect is largely due to a
mistargeting of p21 mRNA in stress granules leading to its degradation. Altering the expression of p21 itself, either by
depleting CUGBP1 or p21, promotes bortezomib-mediated apoptosis.
Conclusions/Significance: We propose that one key mechanism by which apoptosis is inhibited upon treatment with
chemotherapeutic drugs might involve upregulation of the p21 protein through CUGBP1.
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Introduction
The proteasome is a large multi-subunit complex responsible for
the degradation of various proteins, including cell cycle regulators
and apoptotic factors, via both ubiquitin-dependent and –
independent mechanisms [1,2]. Incubation of proliferating cells
with proteasome inhibitors induces apoptosis [3–6]. The protea-
some inhibitor bortezomib has recently been approved for clinical
use, showing strong antitumor activity in multiple myeloma and
other hematological tumors [7,8]. However, solid tumors of
different organ origins are refractory to bortezomib, and this
resistance is also observed in cancer cell lines derived from solid
tumors [9–12]. The mechanisms by which cancer cells resist to
bortezomib are still largely unknown, although it is postulated that
this resistance might involve the activation of a general stress
response [9–13].
We have recently reported the formation of stress granules
following treatment with bortezomib [14]. Stress granules (SG) are
cytoplasmic bodies whose formation is induced by various types of
stress such as ionizing radiations [15], hypoxia [16], viral infection
[17,18], and proteasome inhibitors [14,19,20]. Since such stress
stimuli are known to inhibit translation initiation, it was speculated
that SG represent sites where the translation of specific mRNAs is
repressed [21–24]. SG might repress translation in part by limiting
the interaction of mRNAs with ribosomes [21,22]. The potential
role of SG in translation repression is supported by several reports
showing that specific mRNAs are inefficiently repressed when
RNA-binding proteins, which contribute to SG formation, are
altered [15,18,20,25,26]. These foci also contain small ribosomal
subunits, translation initiation factors and signaling molecules
[21,27]. In accordance with the proposed role of SG as storage
sites for untranslated mRNAs, these foci are devoid of large
ribosomal subunits [28]. Once the stress is relieved SG gradually
disassemble, leading to the recovery of translation required for cell
survival. It is thus postulated that SG formation is central to the
stress response, which reprograms gene expression towards the
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stress and thus survive [21]. Indeed, the induction of SG upon
exposure to hypoxia [29], oxidative stress (e.g. arsenite) [19], or
bortezomib treatment [14] leads to resistance of tumor cells to
apoptosis. One mechanism underlying such resistance appears to
involve the sequestration and inactivation of pro-apoptotic factors
such as RACK1 and TRAF2 in SG [29–31]. Other mechanisms
by which SG may antagonize apoptosis could involve the
sequestration of mRNA encoding key anti-apoptotic factors within
SG, thereby preventing their degradation. Although such
mechanisms have not been formally demonstrated, evidence
nevertheless exists suggesting a role for SG in the regulation of
mRNAs encoding anti-apoptotic proteins [15,20,32].
We and others have previously suggested a potential role of SG
in the regulation of one such antiapoptotic factor, namely the
expression of p21
WAF1/CIP1 mRNA [20,32]. p21 is a well-known
cyclin-dependent kinase inhibitor induced following various stress
stimuli, including proteasome inhibitors. As a proliferation
inhibitor, p21 was suggested to play a role in tumor suppression
by promoting cell cycle arrest or by inducing apoptosis [33–36].
Conversely, other laboratories reported that stress-induced
upregulation of p21 can protect tumor cells from apoptosis
[37–41]. Whether p21 upregulation promotes resistance to
apoptosis mediated by proteasome inhibitors in cancer cells is
currently unknown. It is well established that stress-mediated
upregulation of p21 involves transcriptional mechanisms. Other
studies indicate that p21 expression is also regulated post-
transcriptionally, mainly at the level of mRNA stability, in
response to various SG-inducing stress stimuli such as UV
radiation [42,43] and oxidative stress [32]. We have previously
shown that the proteasome inhibitor MG132 induces the
sequestration of p21 mRNA into SG, which correlates with its
stabilization [20].
Due to its short half-life, p21 mRNA is expressed at very low
levels under normal growth conditions [20,42,43]. We showed that
treatment of HeLa cells for 3 to 6 h with proteasome inhibitors
such as MG132 or lactacystin induces both SG formation and p21
mRNA accumulation, due in part to stabilization of the latter [20].
CUGBP1 belongs to the CELF family of RNA binding proteins
and is aberrantly expressed in myotonic dystrophy type I [44–46].
CUGBP1 controls mRNA splicing in the nucleus. In the
cytoplasm, CUGBP1 was shown to promote either mRNA decay
[44,47–52] or translation of its associated mRNAs [44–46,53].
The translational function of CUGBP1 has been investigated in
normal cells. These studies showed that CUGBP1 increases p21
translation in myocytes, thereby leading to their differentiation
[46,53], and in aged normal fibroblasts, where it results in a
senescent-like phenotype [54]. The role of CUGBP1 in apoptosis
was unsuspected until recently. Kress and coll. generated mice in
which the Cugbp1 gene was inactivated by homologous recombi-
nation [55]. Although Cugbp1
2/2 mice are viable, they display
significant perinatal mortality and growth retardation. Moreover,
germ cells derived from Cugbp1
2/2 mice are more prone to
apoptosis than wild-type cells [55]. Recent studies have shown that
CUGBP1 accumulates into SG following arsenite treatment,
indicating that CUGBP1 might play a role in cellular stress
response [32,56].
In the study herein, we identified CUGBP1 as a factor required
for p21 mRNA stabilization upon bortezomib treatment. We
show here that CUGBP1 accumulates into SG following
bortezomib treatment, together with its associated p21 mRNA.
Upon depletion of CUGBP1, bortezomib-mediated p21 mRNA
localization in SG and therefore its stabilization are lost, thereby
leading to its misexpression. Altering the expression of p21 either
by depleting CUGBP1 or p21 itself promotes bortezomib-
mediated apoptosis. Our study unveils p21 as a potential
therapeutic target.
Results
Bortezomib induces p21 mRNA accumulation followed
by its translation
We have previously shown that bortezomib induces the
reversible formation of SG [14]. We therefore analyzed the
expression of p21 during the assembly and disassembly of SG
following bortezomib addition. In HeLa cells, SG formation,
which occurred 4 h after bortezomib treatment (Fig. 1A; center
panel) correlated with a drastic increase in the steady-state level
of p21 mRNA (Fig. 1B). Time course analysis of SG formation
shows that the percentage of cells forming SG remains high
between 4 and 7 h of bortezomib treatment. (Fig. S1A). At those
stages, however, p21 mRNA was not being efficiently translated
(Fig. 1C and Fig. S1B), despite its sustained accumulation (Fig.
S1C). Prolonged treatment with bortezomib (10 h) resulted in
complete SG disassembly (Fig. 1A; bottom panel, and Fig. S1A)
and concomitant efficient p21 protein production (Fig. 1C and
Fig. S1B), despite some reduction (30–40%) in p21 mRNA level
(Fig. 1B). We obtained similar results using two other cell lines,
namely the MCF-7 human breast carcinoma and Calu-I human
lung carcinoma cells (Fig. S2A–B). We next used immunofluo-
rescence to corroborate our results of p21 expression. We found
that p21 was below the detection threshold in untreated cells or
upon treatment with bortezomib for 4 h (Fig. 1D; top and center
panels, respectively, and Fig. S1A) to 7 h (Fig. S1A). Very few
(,5%) untreated cells or cells treated with bortezomib for 4–7 h
did express p21, however, which might either reflect a stressed
state or normal cell cycle arrest in these cells. However, when
bortezomib treatment was extended to 10 h, p21 was highly
expressed and accumulated in the nucleus, concomitantly with
SG disassembly (Fig. 1D; bottom panel; see also Fig. S1A). To
ensure that the proteasome is still inhibited at the time when SG
disassembled, we monitored the expression of a reporter GFP
fused to a proteasome-targeting sequence (GFPu). In the absence
of any proteasome inhibitors, the GFPu protein is constitutively
degraded by the proteasome [57,58]. Treatment of these GFPu-
expressing cells with bortezomib prevented the degradation of
GFPu protein, which accumulated. This accumulation of GFPu
persists even after prolonged treatment with bortezomib for 10 h
and beyond (Fig. S3A and data not shown), indicating that the
activity of the proteasome was not recovered. Moreover,
prolonged treatment (10 h and beyond) with bortezomib resulted
also in the accumulation of proteasome substrates such as p27
[59–61] (Fig. S3B and data not shown) and p53 [59–61] (data not
shown). These results indicate that the disassembly of SG
occurred without reactivation of the proteasome. Nuclear p21
has previously been shown to promote cell cycle arrest, mainly by
interfering with cyclin E/cdk2 activity [62]. On the other hand,
other studies have reported that nuclear p21 accumulation
promotes the formation of cyclin D-cdk4 complexes in cancer
cells, thus contributing to increased proliferation and reduced
apoptosis in tumors [63]. Therefore, we investigated whether
nuclear p21 accumulation which occurred concomitantly with
SG disassembly (cf. 10 h following bortezomib treatment; Fig. 1D,
S1A, and S1D) might reflect cell cycle arrest. Time course-FACS
analysis of cell cycle progression shows that bortezomib treatment
does not affect cell cycle (Fig. 1E). As a control for cell cycle arrest
we used nocodazole [64], which as shown in Figure 1E stops
cellular progression at G2/M. p21 was also shown to inhibit
p21
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apoptosis signal-regulating kinase 1 (ASK1) and caspase-3 in the
cytoplasm [40,65,66]. We found that protracted treatment with
bortezomib (16 h) induces a significant accumulation of p21 in
the cytoplasm (Fig. S1A; bottom-right panel; see also Fig. S1E),
which may reflect a role of this protein in antagonizing
bortezomib-mediated apoptosis (see below). Overall, the results
thus far show that bortezomib-mediated p21 upregulation
involves two steps: (i) the initial accumulation of p21 mRNA,
which correlates with SG formation, and (ii) the secondary
translation of p21 mRNA, which correlates with SG disassembly.
This pattern of events suggests that SG might serve as foci for
the accumulation of p21 mRNA in a translationally repressed
form.
Bortezomib treatment induces p21 mRNA segregation
with SG and its stabilization
We next assessed whether accumulating p21 mRNA was
localized in bortezomib-induced SG. For that purpose, we used
fluorescent in situ hybridization (FISH) to visualize p21 mRNA in
fixed HeLa cells, using fragile X mental retardation protein
(FMRP) [14,67,68] as a marker for staining SG (Fig. 2A).
Resulting staining reflected a typical localization of FMRP in the
cytoplasm in control experiments (Fig. 2A, panels 8 and 11), and in
SG upon bortezomib treatment (Fig. 2A, panels 2 and 5). FISH
showed a barely detectable p21 mRNA staining in untreated cells
(Fig. 2A, panel 7; see also Fig. S4A and S4C), in keeping with the
low amount of p21 mRNA and protein observed under normal
growth conditions (cf. Fig. 1B–C and S1C). Bortezomib induced
Figure 1. Bortezomib upregulates p21 mRNA expression. (A) HeLa cells were treated with 2 mM bortezomib for 4 h or 10 h, fixed,
permeabilized, and then processed for immunofluorescence using antibodies against different SG markers. DAPI is used as a nuclear stain. Pictures
were taken using 63X objective. The percentage of cells harboring SG (.3 granules/cell) from five different fields and three different experiments
containing a total of 1000 cells is indicated. (B) qRT-PCR of p21 mRNA. Following treatment with bortezomib for the indicated period, cells were
collected and total RNA content was then isolated. The amount of p21 was quantified by real time-PCR relative to GAPDH mRNA using the DDCt
method. Results are expressed as the mean 6 SEM (error bars) of triplicate measurements. (C) HeLa cells were treated with 2 mM bortezomib for the
indicated time, and the level of p21 was analyzed by western blotting using specific antibodies (top panel). Tubulin is used as a loading standard. The
amount of p21 was determined by quantitation of the signals on films by densitometry using Adobe Photoshop software and expressed as a
percentage relative to the amounts of tubulin. The results are representative of five different experiments. (D) HeLa cells were treated as in (A). p21
protein was detected using anti-p21 antibodies and SG were visualized with anti-FMRP antibodies. (E) Bortezomib does not affect cell cycle at the
time points analyzed. Cells were treated with 2 mM bortezomib or with 0.8 mg/ml nocodazole for the indicated interval, collected, washed with PBS,
and then fixed with 3% paraformaldehyde for 20 min. Cells were washed with PBS, stained with DAPI (1 mg/mL) and analyzed by flow cytometry.
doi:10.1371/journal.pone.0020254.g001
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of cells, as assessed by FISH using the targeted (antisense) probe
(Fig. 2A, panels 1 and 3; see also Fig. S4A–B). Quantification of
the intensity of p21 mRNA FISH signal in SG compared to the
cytoplasm revealed that the major fraction (,80%) of p21 mRNA
was associated with SG (Fig. 2B; left panel; see also Fig. S4B).
Background FISH signal was detected in SG and in the cytoplasm
using the untargeted (sense) probe (Fig. 2A, panels 4 and 6, and
Fig. 2B; center and right panels). Similar background signal was
detected in the cytoplasm of bortezomib-treated cells using the
antisense probe (Fig. 2A, panels 1 and 3; see also the right panel of
Fig. 2B for quantification), as compared to the signal obtained
using the sense probe (Fig. 2A, panels 4 and 6, and the right panel
of Fig. 2B). The SG-linked FISH signal which is detected using
antisense probe was specific to p21 mRNA since it was lost in cells
treated with p21-targeted siRNA to deplete the transcript (Fig. 2C;
Figure 2. The accumulation of p21 mRNA following bortezomib treatment involves its stabilization and correlates with its
segregation in SG. (A–B) Bortezomib induces p21 mRNA segregation into SG. Following treatment with bortezomib (2 mM) for 4 h, HeLa cells were
fixed, permeabilized, and then incubated with 3 nM of an Alexa Fluor 488-labeled antisense RNA probe to detect p21 mRNA (panels 1–3 and 7–9) or
with the Alexa Fluor 488-labeled sense probe as control (panels 4–6 and 10–12). SG were detected using anti-FMRP antibodies. The percentage of SG
(.3 granules/cell) under each condition is indicated at the bottom of the right panels. The percentage of cells harboring SG positive for p21 mRNA is
indicated at the right. Shown are typical results from five different fields and three different experiments containing a total of 1000 cells. (B)
Densitometry quantification of FISH signal with Adobe Photoshop software. The number of pixels and mean intensities were recorded for the
selected regions (SG, cytoplasm and background) using Photoshop. The mean intensity was multiplied by the number of pixels for the region
selected in order to obtain the absolute intensity. The absolute intensity of the background region was subtracted from each region of interest. In
order to compare the intensity between two given regions of interest, relative intensities were next calculated. Relative intensities correspond to the
absolute intensities normalized according to the absolute intensity of the region of reference. (C–D) p21 mRNA FISH signal is lost upon p21
knockdown. Cells were treated with p21 or control siRNA. Seventy-two hours later, cells were treated with bortezomib (2 mM for 4 h) in order to
induce SG, and then processed for FISH to detect p21 mRNA coupled with immunofluorescence in order to visualize SG (C). In (D), cells were lysed
and their RNA content analyzed for the expression levels of p21 mRNA using qRT-PCR. p21 mRNA levels were standardized against the non-target
GAPDH mRNA and expressed as a percentage of the initial mRNA levels (i.e. at time zero) present at each time point. The error bars correspond to the
SD of three independent experiments. (E–F) Bortezomib induces p21 mRNA stabilization. HeLa cells were left untreated (E) or were treated with
bortezomib (2 mM) for 4 h (F). Cells were then incubated with 5 mg/ml actinomycin D for 30 minutes and collected at the indicated time points
following the incubation. Total RNA was isolated and the level of p21 mRNA expression was determined by qRT-PCR, standardized against GAPDH
mRNA, and expressed as a percentage of the initial mRNA levels (i.e. at time zero) present at each time point. The error bars correspond to the SD of
three independent experiments.
doi:10.1371/journal.pone.0020254.g002
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affect SG formation, as suggested by the localization of several SG
markers (Fig. 2C, and data not shown) ruling out the possibility
that the loss of SG-linked FISH signal observed in p21-depleted
cells was due to a general cellular failure to form SG. As expected,
prolonged treatment (10 h) of cells with bortezomib induces SG
disassembly and p21 mRNA localization to the cytoplasm and to
the nucleus (Fig. S4A and S4C; bottom-left panels). At this time,
however, the overall p21 mRNA FISH signal is weaker than the
one observed in cells treated with bortezomib for 4 h (Fig. S4A;
compare bottom-left with center-left panel), in keeping with the
decreased amount of p21 mRNA as measured by qRT-PCR
following SG disassembly (Fig. 1B). Overall, the results (Fig. 2A–B
and S4A–B) show that p21 mRNA is quantitatively recruited to
bortezomib-induced SG. We then assessed the possible contribu-
tion of p21 mRNA localization in SG in its accumulation. We
have previously reported that the formation of bortezomib-
induced SG requires heme-regulated inhibitor kinase (HRI) [14].
Thus, we examined whether altering SG formation via HRI
depletion affects p21 mRNA accumulation. We found that HRI
depletion indeed prevented p21 mRNA accumulation following
bortezomib treatment, as assessed by qRT-PCR (Fig. S5A). HRI
was efficiently depleted as assessed by western blotting (Fig. S5B),
and as expected, its depletion completely prevented SG formation
(Fig. S5C). Altogether, these results show that bortezomib
treatment induces p21 mRNA accumulation in SG. We then
addressed the hypothesis that this p21 mRNA accumulation
reflects its stabilization. For this purpose, we determined the effect
of bortezomib on p21 mRNA stability in the presence of
actinomycin D. Upon inhibition of de novo RNA synthesis with
actinomycin D, the relative half-life of p21 mRNA was increased
from 60 min 610 min in untreated cells to .3 h upon
bortezomib treatment (Fig. 2E–F), reflecting bortezomib-induced
accumulation of p21 mRNA (Fig. 1B). As shown in Figure 2E
however, the p21 mRNA decay included a plateau phase. This
indicated that the p21 mRNA decay may not be a first order
process. This type of decay occurs if two or more degradation
processes with different rate constants are involved. Subpopulation
of p21 mRNAs may be restricted to discrete subcellular locations
that prevent their decay. Also, the decay of some p21 mRNAs may
be mediated by competing pathways and/or decay mechanisms
utilizing distinct trans-acting complexes, which could then affect
their decay rates. Nevertheless, our results suggest that p21 mRNA
segregation in SG contributes to its stabilization and accumulation
upon bortezomib treatment. Next we sought to determine which
factor is involved in p21 mRNA localization in SG.
Role of CUGBP1 in p21 mRNA accumulation and
subsequent translation during bortezomib treatment
The SG components HuR and CUGBP1 have been shown to
bind p21 mRNA, thereby regulating its expression [14,54,69].
While HuR promotes p21 mRNA stabilization through interac-
tion with its AU-rich element in the 39-untranslated region,
CUGBP1 interacts with the GC-rich element in the 59 region of
p21 mRNA coding sequence and promotes its translation in
senescent fibroblast cells. We investigated the role of these two
proteins in the upregulation of p21
WAF/CIP1 observed upon
proteasome inhibition in HeLa cells. We found that depletion of
HuR had no effect or rather slightly increased p21 protein
expression following bortezomib treatment (data not shown).
Depletion of CUGBP1 using two specific siRNAs had no effect on
p21 protein expression under normal growth conditions but
prevented bortezomib-mediated p21
WAF/CIP1 upregulation as
assessed by western blot analysis using anti-p21 antibodies
(Fig. 3A and data not shown). These results indicate that CUGBP1
promotes p21 upregulation upon proteasome inhibition. As a
first step to investigate how CUGBP1 up-regulates p21 upon
proteasome inhibition, we performed co- localization studies
between CUGBP1 and p21 mRNA. Under normal growth
conditions, CUGBP1 is mostly nuclear [32,56] (Fig. S4C, panel
2). Arsenite induces the localization of a fraction of CUGBP1 in
SG [32,56], and our immunofluorescence experiments showed
that CUGBP1 was also recruited into bortezomib-induced SG
(Fig. 3B). Quantification of these immunofluorescence data show
that a significant fraction (,45%) of total CUGBP1 is present in
SG (Fig. 3B–C) where it co-localized with p21 mRNA (Fig. 3B and
3D–E) following treatment with bortezomib. Under these
conditions, about 50% of CUGBP1 is nuclear (Fig. 3B–C) and
only residual staining of CUGBP1 is detected in the cytoplasm
(Fig. 3B and 3D). Prolonged treatment with bortezomib (10 h)
resulted however in nuclear localization of most CUGBP1 (Fig.
S4C). At this time we detected also some p21 mRNA FISH signal
in the nucleus. However, and as mentioned above, the overall p21
mRNA FISH signal at 10-h bortezomib treatment is reduced (Fig.
S4A and S4C), as compared to 4 h treatment (Fig. S4A; see also
Fig. 2A) at which time point most of p21 mRNA (,80%) co-
localized with CUGBP1 in SG (Fig. 3B and 3D–E). Overall, our
results (Fig. 3B) indicate that bortezomib treatment induces
CUGBP1-p21 mRNA co-localization in SG. CUGBP1 might
thus bind to p21 mRNA and recruit it to SG where it accumulates.
The latter assumption would therefore predict that CUGBP1
depletion should trigger p21 mRNA degradation, which would
explain the low amount of p21 protein following prolonged
proteasome inhibition in CUGBP1-depleted cells (Fig. 3A).
Indeed, we first confirmed that CUGBP1 binds to p21 mRNA
under bortezomib conditions, as assessed by immunoprecipitating
CUGBP1 (Fig. 3F) followed by quantitative RT-PCR (qRT-PCR)
to detect associated p21 mRNA (Fig. 3G). This binding was
specific, as suggested by the finding that control p27 mRNA was
not recovered in CUGBP1 immunoprecipitates (Fig. 3G). Second,
the steady-state p21 mRNA level significantly decreased in
CUGBP1-depleted cells following proteasome inhibition
(Fig. 3H). Depletion of CUGBP1 had however no effect on the
steady-state level of p21 mRNA in untreated cells (Fig. S6A),
suggesting that CUGBP1 is not required to maintain the basal
level of the p21 mRNA. We then tested the possibility that the
decreased level of p21 mRNA in CUGBP1-depleted cells upon
bortezomib treatment might be consistent with a more rapid
degradation of p21 mRNA. Indeed, the half-life of p21 mRNA in
bortezomib conditions decreased from .3 h in mock-depleted
cells (Fig. 4A) to 90 min 615 min in CUGBP1-depleted cells
(Fig. 4B). Depletion of CUGBP1 was efficient, as evidenced by
both western blot analysis (Fig. 4C) and immunofluorescence
(Fig. 4D), using anti-CUGBP1 antibodies. However, quantification
of the localization of several SG markers (Fig. 4D, and data not
shown) indicated that CUGBP1 depletion per se did not affect SG
formation. This result ruled out the possibility that the
destabilization of p21 mRNA observed in CUGBP1-depleted cells
upon bortezomib treatment (Fig. 4A–B) was due to a cellular
failure to form SG. One likely possibility of the destabilisation of
p21 mRNA observed in CUGBP1-depleted cells is because it is no
longer recruited to SG. We then assessed if CUGBP1 depletion
affects the accumulation of p21 mRNA in SG using FISH. SG
were visualized by immunofluorescence using antibodies to either
Ras GTPase-activating protein-binding protein 1 G3BP1 (Fig. 4D)
or FXR1 (data not shown). Whereas the major fraction of p21
mRNA (,70%) is present in SG in over 60% of mock-depleted
cells upon treatment with bortezomib (Fig. 4D–E), less than 30%
p21
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localization in SG (Fig. 4D). Indeed, the large fraction of
CUGBP1-depleted cells (,80%) has a barely detectable FISH
p21 mRNA signal in SG and in the cytoplasm (Fig. 4D and 4F).
Under those bortezomib conditions, quantification of the intensity
of p21 mRNA FISH signal showed that CUGBP1 depletion
decreased this signal to 30–40%, as compared to mock-depleted
cells where most p21 mRNA FISH signal was detected in SG
(Fig. 4G). This effect seems to be specific since under the same
conditions, depletion of CUGBP1 does not affect the association of
the non-target GAPDH mRNA [47] with SG as assessed by
immunofluorescence coupled with FISH (Fig. S7). Overall, our
results show that CUGBP1 depletion significantly prevented
bortezomib-induced p21 mRNA accumulation, which is likely
due to its mistargeting in SG. As aforementioned, CUGBP1
depletion does not affect p21 mRNA steady-state levels in normal
growth conditions (Fig. S6A) and we found that this is also the case
under staurosporine treatment (Fig. S6B), a SG-free apoptotic
condition [70] (Fig. S6D). These results suggest that CUGBP1 is
not required to maintain the steady-state levels of p21 mRNA in
the cytoplasm. On contrary, CUGBP1 seems to be required for
bortezomib-induced p21 mRNA accumulation in SG (Fig. 3H,
Figure 3. CUGBP1 binds to p21 mRNA and promotes its accumulation and expression upon bortezomib treatment. (A–D) Seventy-
two hours following transfection with CUGBP1, or control siRNAs, HeLa cells were treated with bortezomib (2 mM) for either 10 h (A) or 4 h (B). (A)
Protein extracts were prepared and analyzed by western blot to detect CUGBP1, p21, and G3BP1 proteins (loading standards) using the appropriate
antibodies. The percentages of CUGBP1 knockdown and p21 expression were determined by quantitation of the signal on films by densitometry
using Adobe Photoshop as described in Figure 1C. Shown are typical results of three experiments. (B–D) p21 mRNA is quantitatively recruited into SG
where it co-localizes with CUGBP1. (B) Cells were processed for FISH to detect p21 mRNA coupled to immunofluorescence to visualize SG using
antibodies against CUGBP1 and G3BP1. The percentage of SG (.3 granules/cell) is indicated at the bottom of the right panel. The percentage of cells
harboring SG positives for p21 mRNA is also indicated on the right of the figure. Shown are typical results from five different fields and three different
experiments containing a total of more than 1000 cells. (C–D) Densitometry quantification of CUGBP1 immunofluorescence signal in SG versus nuclei
(C) and in SG versus the cytoplasm (D) using Adobe Photoshop software as described in Figure 1. (E) Densitometry quantification of p21 mRNA FISH
signal was done as described in Figure 2. (F–G) HeLa cells were treated with bortezomib for 4 h and their extracts were used to immunoprecipitate
CUGBP1 with anti-CUGBP1 antibodies and with IgG as a control. IP: Immunoprecipitate; FT: flow-through following immunoprecipitation; Total: the
input used for immunoprecipitation. (F) Proteins were analyzed by western blot for CUGBP1 immunoprecipiation. (G) mRNAs were isolated from each
immunoprecipitate and quantified by qRT-PCR. The amounts of p21 mRNA and p27 mRNA (as control) were normalized against GAPDH mRNA. (H)
HeLa cells were treated with CUGBP1-specific siRNA, or with control (non-specific) siRNA as described above, incubated with 2 mM bortezomib for
either 4 or 10 h, lysed, and their total RNA isolated and analyzed for p21 mRNA levels by qRT-PCR. The amount of p21 mRNA was normalized against
that of GAPDH mRNA as described in Figure 2.
doi:10.1371/journal.pone.0020254.g003
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accumulation by recruiting the transcript in SG, although we do
not exclude that CUGBP1-mediated p21 mRNA accumulation
involves additional mechanisms. Nevertheless, these results showed
that CUGBP1 acts as a positive effector of p21 upregulation upon
proteasome inhibition.
p21 upregulation prevents bortezomib-mediated cell
death
Having revealed CUGBP1-mediated p21 mRNA accumulation
as a pathway that promotes p21 upregulation following bortezo-
mib treatment, we then investigated whether targeting this
pathway might induce apoptosis. We have previously shown that
suppressing SG formation induces massive apoptosis following
bortezomib treatment [14]. We thus tested the effect of a
decreased p21
WAF/CIP1 expression on apoptosis upon bortezomib
treatment. HeLa cells treated with p21-specific or control siRNAs
were exposed to bortezomib (2 mM) for 16 h, and apoptosis was
then measured (i) by western blot analysis of the cleavage of
caspase-3, one of the main effectors of caspase-dependent
apoptosis, as well as (ii) with the percentage of annexin V-positive
cells detected using flow cytometry. Depletion of p21
WAF/CIP1 was
assessed by western blot (Fig. 5A) and did not induce significant
apoptosis per se (Fig. 5A–B). Following a 16-h incubation with
bortezomib, however, p21
WAF/CIP1 depletion resulted in signifi-
cant (30%) caspase-3 cleavage (Fig. 5A), while promoting apoptosis
in a high percentage (55%) of cells (Fig. 5B). Similar results
were obtained using a different p21-specific siRNA (data not
Figure 4. Reducing CUGBP1 levels prevents bortezomib-mediated p21 mRNA stabilization and accumulation in SG. (A–B) HeLa cells
were treated with non-specific (A), or with CUGBP1-directed siRNA (B), incubated with bortezomib (2 mM) for 4 h, and actinomycin D (5 mg/ml) was
then added for a period of 30 minutes. Cells were collected at the indicated time points following the incubation and total RNA was isolated. The
level of p21 mRNA expression was measured by qRT-PCR, standardized against GAPDH mRNA, and expressed as a percentage of the initial mRNA
levels (i.e. at time zero) present at each time point. The error bars correspond to the SD of three independent experiments. (C) Depletion of CUGBP1
was assessed by western blot using anti-CUGBP1 antibodies and quantified as described in Figure 3. (D) HeLa cells were treated with CUGBP1-specific
siRNA, or with control siRNA as described above, treated with bortezomib (2 mM) for 4 h, and then fixed, permeabilized, and incubated with 3 nM of
an Alexa Fluor 488-labeled antisense RNA probe to detect p21 mRNA. SG were detected using anti-G3BP1 antibodies. Depletion of CUGBP1 was
assessed by immunofluorescence using anti-CUGBP1 antibodies. The percentage of SG is indicated at the bottom of the right panels. The percentage
of cells harboring SG positives for p21 mRNA is also indicated. Those percentages are representative of typical results from three different
experiments counting more than 1000 cells. (E–F) Densitometry quantification of p21 mRNA FISH signal in SG versus the cytoplasm in mock-depleted
cells (E) and CUGBP1-depleted cells (F) as described in Figure 1. (G) Densitometry quantification of p21 mRNA FISH signal in SG in mock-depleted
versus CUGBP1-depleted cells as described in Figure 2.
doi:10.1371/journal.pone.0020254.g004
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p21
WAF/CIP1 depletion promoted bortezomib-induced apoptosis in
Calu-I carcinoma cells (data not shown). Taken together, the
present results thus strongly indicate that p21 upregulation can
promote cancer cell resistance to bortezomib.
To further confirm the role of p21 in promoting resistance to
bortezomib treatment, we performed clonogenic survival assays.
HeLa cells were treated with p21-specific or control siRNAs,
and following incubation with bortezomib, were washed to
remove the drug, diluted and replated in fresh medium for 10 d,
at which point colonies were counted. The results clearly
showed that depleting p21
WAF/CIP1 significantly (40%) de-
creased cell survival and proliferation following treatment with
bortezomib (Fig. 5C). Overall, the present data suggest that
resistance of cancer cells to bortezomib-induced apoptosis
involves p21
WAF/CIP1 upregulation.
Figure 5. p21 depletion promotes bortezomib-mediated apoptosis. (A) HeLa cells were transfected with p21-directed siRNA, or with a
control siRNA. Forty-eight hours later, cells were collected and their protein extracts analyzed by western blot for the amount of p21 (top panel) using
anti-p21 antibodies. The activation of caspase-3 was analyzed using anti-caspase-3 antibodies (bottom panel). CP: cleaved product. Tubulin is used as
a loading standard (middle panel). The amount of p21 was determined by quantitation of the signals on films by densitometry using Adobe
Photoshop software and expressed as a percentage relative to the amounts of tubulin. The percentage of caspase-3 cleavage was calculated by
quantifying the signal of the caspase-3 cleaved product relative to the amount of total caspase-3. Shown are representative results of three different
experiments. (B) Following treatment with p21-specific siRNA or with a non-specific siRNA, HeLa cells were incubated with bortezomib for 16 h, then
stained with annexin V-FITC and PI, and analyzed by flow cytometry. The percentage of total dead or dying cells (indicated at the top of each panel)
was defined as the sum of early (lower right box) and late (upper right box) apoptosis and corresponds to the mean 6 SEM from three independent
experiments. V: viable cells; E.A: early apoptosis; L.A: late apoptosis. (C) Clonogenic assays. Following treatment with p21-specific siRNA or with a non-
targeted siRNA, HeLa cells were incubated with bortezomib for 16 h, trypsinized, counted, replated in the absence of drug, and incubated for 10 d.
Prior to counting colonies, cells were fixed, and then dried. Populations .50 cells were counted as one surviving colony. Data were calculated as the
percentage of surviving colonies relative to the number found in control (untreated) plates. Results are expressed as the mean of triplicate
measurements. (D–E) Reducing CUGBP1 levels promotes bortezomib-induced apoptosis. HeLa cells were treated with CUGBP1-specific siRNA, or with
control siRNA. Seventy-two hours later, cells were either collected and their protein extracts analyzed by immunoblotting for the amount of p21,
CUGBP1, tubulin (loading standard), and for caspase-3 activation, using corresponding antibodies (D), or stained with annexin V-FITC and PI, and
analyzed by flow cytometry (E) as described above. In D, the relative expression of p21 and CUGBP1 was determined as described in Figure 3, and the
percentage of caspase-3 cleavage was quantified as described in (A). Shown are typical results of three different experiments. In (C), the percentageo f
total dead or dying cells is indicated at the top of each panel in E and is defined as the sum of early (lower right box) and late (upper right box)
apoptosis and represents the means +/2 s.e.m, from two independent experiments.
doi:10.1371/journal.pone.0020254.g005
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bortezomib-induced apoptosis
The role of CUGBP1 in cancer cell resistance to apoptosis has
not been previously investigated. From the above-described results
(Fig. 3–5), we hypothesized that CUGBP1 might promote
resistance to bortezomib through p21 upregulation. In such a
case, decreasing p21 expression via CUGBP1 depletion should
promote apoptosis following bortezomib treatment. Thus, HeLa
cells treated with CUGBP1-specific or control siRNAs were
exposed to bortezomib (2 mM) for 16 h, and apoptosis was then
assessed by caspase-3 cleavage (Fig. 5D) and annexin V assays
(Fig. 5E). CUGBP1 depletion was confirmed by western blot
(Fig. 5D) and did not induce significant apoptosis per se (Fig. 5D–
E). Under bortezomib conditions, depletion of CUGBP1 induced
cleavage of about 15% of total caspase-3 (Fig. 5D), and resulted in
a significant percentage (30%) of cells undergoing apoptosis
(Fig. 5E).
Discussion
The present study clearly shows that bortezomib treatment of
cancer cells upregulates p21
WAF1/CIP1 expression, which confers
cellular resistance to apoptosis. Bortezomib-mediated p21 upre-
gulation involves p21 mRNA accumulation in SG and its
stabilization through the SG component CUGBP1. Our results
suggest the following two-step model for bortezomib-induced p21
upregulation. In the first step, p21 mRNA is quantitatively
sequestered into SG in a CUGBP1-dependent fashion, thereby
protecting the normally highly unstable p21 mRNA against
degradation, and contributing to its accumulation. The second
step involves SG disassembly, thus releasing the large pool of
accumulated p21 mRNA which is now available for immediate
translation. This creates a massive pulse of p21
WAF1/CIP1 synthesis
that helps preventing apoptosis despite proteasome inhibition by
bortezomib. Our study therefore identified a potential survival
pathway involving both CUGBP1 and p21 which could be
therapeutically targeted to antagonize cancer cell resistance to
bortezomib-mediated apoptosis.
Increasing evidence has implicated p21 as an anti-apoptotic
factor that promotes cancer cell resistance to therapeutic agents. It
has been shown that the treatment of cancer mesothelioma cells
with chemotherapeutic drugs such as Irinotecan induces p21
expression and cellular senescence [71]. Depletion of p21 by
specific short hairpin RNAs in tumor cells in vivo prevents
Irinotecan-induced cell senescence, promotes apoptosis, and
enhances the survival of Irinotecan–treated xenografts in animal
models. p21 expression reduced the survival of Irinotecan–treated
animals xenografted with mesothelioma tumor cells, in keeping
with a potential role of p21 in chemoresistance [71]. Likewise,
doxorubicin-treated breast, lung, and colon carcinoma cells
undergo cellular senescence in vitro, which is characterized by a
constitutively active ATM/ATR-dependent DNA damage re-
sponse and the induction of p21 [72]. Blocking the ATM kinase
with specific inhibitors suppresses p21 expression and induces
apoptosis, suggesting that p21 acts downstream of ATM to
promote cancer chemoresistance. It will be interesting to assess the
hypothesis that chemotherapeutic drugs such as Irinotecan and
doxorubicin can induce p21 upregulation through mechanisms
involving the CUGBP1-SG pathway described in this work. A
recent study has shown that imatinib, a BCR-ABL inhibitor used
for the therapy of chronic myeloid leukemia (CML), downregu-
lates p21 expression at both mRNA and protein levels in sensitive
CML cells, while resistant CML cells exhibit increased p21
expression [73]. Overexpression of p21 mediated by transient
transfection confers resistance to imatinib, a finding consistent
with the hypothesis that p21 upregulation might promote
resistance to chemotherapy. Our study shows that suppressing
the expression of endogenous p21 is sufficient to prevent resistance
to bortezomib-induced apoptosis. Future studies will be conducted
to investigate the possibility that imatinib might prevent the
bortezomib-mediated upregulation of p21 expression, which
would sensitize cancer cells to apoptosis induction by the
proteasome inhibitor.
The mechanisms by which p21 antagonizes apoptosis are not
yet clear. p21 can block apoptosis indirectly by arresting cell cycle
after nuclear binding to cyclin E-CDK2 and cyclin A-CDK2
complexes, or by increasing proliferation by promoting the nuclear
accumulation of cyclin D-CDK4. However, FACS analysis of cell
cycle progression shows that bortezomib does not affect cell cycle
in our in vitro cancer cell model, despite the initial nuclear
accumulation of p21 which is observed upon 10 h of bortezomib
treatment. This result makes unlikely the possibility that p21-
mediated resistance to bortezomib is due to its ability to arrest cell
cycle. Moreover, protracted treatment (16 h) with bortezomib
induces a cytoplasmic localization of p21. Stress-mediated
cytoplasmic translocation of p21 involves its phosphorylation by
kinases such as PKA and Akt [74,75]. Cytoplasmic p21 has been
shown to interact with the apoptotic effector caspase-3, in a PKA-
phosphorylation dependant manner [76], and leading to resistance
to Fas-mediated cell death [77,78]. Alternatively, Akt-phosphor-
ylated p21 can inhibit cell death induced by TNFa and other
stimuli by inactivating ASK1 in the cytoplasm [37,40,75]. This
MAPK kinase kinase activates the Jun N-terminal protein kinase
in response to various genotoxic agents including proteasome
inhibitors, which results with apoptosis [79–81]. Our immuno-
precipitation experiments revealed an interaction between p21
and ASK1 during bortezomib treatment (Unpublished results).
Although speculative at this stage, we propose that p21 inhibits
bortezomib-mediated apoptosis by inactivating pro-apoptotic
factors such as ASK1. Studies are underway to (i) determine the
mechanisms underlying the cytoplasmic translocation of p21 and
(ii) define if ASK1 is the target by which p21 prevents bortezomib-
mediated apoptosis.
Our study also provides evidence that CUGBP1 might act as a
potential factor in resistance to bortezomib-mediated apoptosis by
promoting p21 mRNA stabilization/accumulation and expression.
Previous studies have shown that CUGBP1 promotes p21 mRNA
expression in normal cells by loading the transcript into translating
ribosomes [54]. On contrary, other reports identified CUGBP1 as
a factor that inhibits the expression of its target mRNAs by
promoting their decay in the cytoplasm [47,50,52]. Our study
identified a novel role of CUGBP1 in promoting p21 mRNA
stabilization during proteasome inhibition, which could involve its
recruitment to SG. First, qRT-PCR showed that bortezomib
highly induces p21 mRNA stabilization leading to its accumula-
tion. Second, FISH experiments revealed that the p21 mRNA thus
accumulating is quantitatively recruited to bortezomib-induced
SG. The possible contribution of SG in protecting p21 mRNA
from turnover is supported by findings that bortezomib-induced
p21 mRNA accumulation is lost in HRI-depleted cells, which do
not form SG. Third, actinomycin D experiments show that
CUGBP1 depletion prevents bortezomib-induced p21 mRNA
stabilization. CUGBP1 depletion does not affect, however, SG
formation. This exclude the possibility that p21 mRNA destabi-
lization observed in CUGBP1-depleted cells upon bortezomib
treatment is due to a failure to form SG. Quantification of FISH
data show that CUGBP1 depletion significantly decreased the
overall amount of p21 mRNA, as compared to mock-depleted cells
p21
WAF1/CIP1 Upregulation Promotes Chemoresistance
PLoS ONE | www.plosone.org 9 May 2011 | Volume 6 | Issue 5 | e20254where most of the accumulated p21 mRNA was detected in SG.
These latter results further corroborate our qRT-PCR data
showing that CUGBP1 is required for p21 mRNA accumulation
upon bortezomib treatment. However, CUGBP1 depletion does
not affect the steady-state levels of p21 mRNA under SG-free
conditions tested, further supporting previous reports [47,50,52]
which indicate that CUGBP1 may not act as a general stabilizing
factor in the cytoplasm. We suggest that CUGBP1 promotes p21
mRNA stabilization upon bortezomib treatment indirectly by
inducing its recruitment into SG. However, one cannot exclude
the possibility that CUGBP1 is not essential for recruiting p21
mRNA to SG, but is required instead for sequestering p21 mRNA
in these structures. In any case however, our results show that
under bortezomib conditions, CUGBP1 is required for p21
mRNA segregation in SG thus promoting its stabilization. At this
stage, the mechanism responsible for the stabilization of p21
mRNA in SG remains to be determined. In general, destabiliza-
tion of the mRNA involves both removal of its 59-end cap
structure (or decapping) and deadenylation of its polyA tail,
followed by exoribonuclease digestion from both ends. Proteins
that protect either the cap structure or the polyA tail, such as
eIF4E and PABP, respectively, have been identified as SG
components [82,83]. In contrast, enzymes that activate decapping
or deadenylation, such as Dcp1a and PARN, respectively, are
absent from SG [82,84]. Thus, there is evidence that SG might
protect p21 mRNA from degradation by isolating it from
destabilizing factors, and CUGBP1 might promote p21 mRNA
stabilization and accumulation either by recruitment or seques-
tration into SG. As a decaying factor, CUGBP1 was shown to
interact directly with the PARN deadenylase to facilitate the
removal of the poly(A) tail and thereby destabilize its target
mRNAs [48]. It is thus tempting to speculate that the sequestration
of CUGBP1 in SG prevented its association with PARN, thus
protecting the associated p21 mRNA from turnover in SG. The
association of CUGBP1 with p21 mRNA is likely to be subject to
regulation by phosphorylation via the action of cyclin D3-cdk4/6
[85]. Interestingly, the residue targeted for phosphorylation by
cyclinD3-cdk4/6 (Ser302) lies within the linker region of CUGBP1
[85], which has been shown to be required for localization in SG
upon arsenite treatment [56]. Future investigations should
determine if CUGBP1 phosphorylation at Ser302 is required for
its localization in SG, as a prerequisite to p21 mRNA
accumulation. Upon disassembly of SG, a large fraction of the
p21 mRNA pool becomes available for rapid translation, thereby
creating a transient pulse of high p21 expression. Previous studies
have shown that CUGBP1 promotes p21 translation in senescent
cells through binding to the GC-rich element in the 59 region of
p21 mRNA and loading of the mRNA onto ribosomes [54].
Following SG disassembly, therefore, CUGBP1 might also
enhance p21 mRNA translation by promoting its association with
ribosomes, although this remains to be demonstrated in a future
study. In addition to GC-rich element, p21 mRNA contains two
other regulatory elements, namely a AU-rich element and a GU-
rich sequence located in its 39-untranslated region. It is unlikely
that the GU-rich element plays a role in the upregulation of p21
mRNA during proteasome inhibition, since this sequence is known
to promote mRNA destabilization [49]. In contrast, the AU-rich
element of p21 mRNA has been shown to confer p21 mRNA
stabilization through its association with the RNA-binding protein
HuR [43,86–88]. However, our results show that HuR is
dispensable for p21 mRNA accumulation during bortezomib
treatment, suggesting that the AU-rich element is unlikely to be
involved in the mechanism leading to p21 mRNA stabilization
under bortezomib treatment. Studies are in progress to identify the
cis-acting elements of p21 mRNA that interact with CUGBP1 in
promoting localization and accumulation of this mRNA in SG. In
addition to p21 mRNA, CUGBP1 might also promote localization
of other mRNAs encoding antiapoptotic proteins in SG, thus
leading to their accumulation. Several mRNAs encompassing GC-
rich sequences in their 59-region encode survival factors involved
in the malignant phenotype, such as vascular endothelial growth
factor (VEGF) and survivin [89], which could be potential targets
of CUGBP1. Future studies will determine the role of CUGBP1 in
the regulation of anti-apoptotic factors such as VEGF and survivin
during chemotherapy.
Conclusions
The present study has identified p21
WAF1/CIP1 and its
regulatory protein CUGBP1 as key players in the inhibition of
apoptosis observed during treatment with bortezomib. Future
studies should determine whether targeting these two factors might
sensitize tumors to proteasome inhibitors in mouse models.
Materials and Methods
Cell Lines and Cultures
HeLa cervical cancer, Calu-1 lung cancer, and MCF-7 breast
cancer cells were obtained from the American Type Culture
Collection (Manassas, VA; ATCC). Cells were cultured in DMEM
(Sigma, St. Louis, MO) supplemented with 10% fetal bovine
serum (FBS; Sigma), penicillin, and streptomycin (Sigma). 293 cells
stably transfected with green fluorescent protein ubiquitin (GFPu)
were purchased from ATCC and handled as previously described
[57,58].
Drugs and Drug Treatments
Bortezomib was purchased from LC Laboratories (Woburn,
MA) and dissolved in DMSO as a 65 mM stock solution, aliquoted
and stored at 220uC. Bortezomib treatment was performed when
cells had reached 60–80% confluence. Staurosporine was
purchased from Sigma.
Antibodies
Phospho-specific anti-eIF2a and the pan anti-eIF2 were
purchased from Cell Signaling Technology (Beverly, MA). Anti-
HuR, anti-G3BP1, anti-FMRP, anti-FXR1, and anti-eIF4E were
made in-house and have been previously described [14,76]. Anti-
CUGBP1, anti-p21, and anti-HRI antibodies were purchased
from Santa Cruz Biotech (Santa Cruz, CA). The anti-tubulin and
anti-caspase-3 antibodies were obtained from Developmental
Studies Hybridoma Bank (Iowa City, IA), and Cell Signaling
(Danvers, MA), respectively. Anti-p27 and anti-GFP antibodies
were purchased from BD Bioscience and Abcam, respectively.
Small-Interfering RNA (siRNA) Experiments
siRNA-p21 were purchased as validated siRNAs from
Qiagen (Mississauga, ON, Canada). siRNA-CUGBP1, siRNA-
HuR, siRNA-HRI, and siRNA non-targeting control were
obtained from Dharmacon (Lafayette, CO). siRNA transfections
were performed essentially as described [14,76], using Hiperfect
reagent (Qiagen) following the manufacturer’s protocol. Twenty-
four hours before transfection, cells were trypsinized and plated at
a density allowing to reach 60–80% confluence after 24 h. For a
6-well plate, annealed duplexes were used at a final concentration
of 5 nM. Seventy-two hours post-transfection, cells were either
fixed and processed for immunofluorescence, or harvested for
protein extraction.
siRNA-p21: 59 AAGACCATGTGGACCTGTCAC 39
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siRNA-HuR: 59-GGGATAAAGTAGCAGGACA-39
si-HRI: 59-GATCTGAAGTGGAAGCTAA-39
Immunofluorescence and RNA FISH
Following fixation and permeabilization (20 minutes in 3.7%
paraformaldehyde at room temperature followed by a 15-min
immersion in MeOH at 220uC), fixed cells were incubated with
primary antibodies diluted in 0.1% Tween-20/PBS (PBST) for 2 h
at room temperature. After washing with PBST, cells were
incubated with goat anti-mouse/rabbit IgG (H+L) secondary
antibodies conjugated with the Alexa Fluor dye with the
appropriate absorption maximum (405/488/594) for 1 h, washed,
and then mounted.
For FISH experiments, a DNA fragment encompassing the p21
coding region was amplified by PCR using primers fused either
with T3 (p21-forward: 59- AATTAACCCTCACTAAAGG-
GATGTCCGTCAGAACCCATGC-39) or T7 (p21-reverse: 59-
TAATACGACTCACTATAGGGGTTAGGGCTTCCTCTT-
GGAGA-39) minimal promoter sequences. The DNA fragment
encompassing the GAPDH coding region was amplified by PCR
using primers fused either to the T3 (GAPDH-forward: 59-
AATTAACCCTCACTAAAGGGAAACTGTGGCGTGATG-
39) or T7 (GAPDH-reverse: 59-TAATACGACTCACTATA-
GGGTTACTCCTTGGAGGCCATG-39) minimal promoter se-
quences. The amplified fragments were used as templates for
in vitro transcription to produce either a p21 or GAPDH antisense
RNAs from the T7 promoter, or p21 and GAPDH sense RNAs
from the T3 promoter, using the FISH Tag RNA Green Kit with
Alexa Fluor 488 (Invitrogen, Burlington, ON, Canada). In the
latter technique, in vitro transcription incorporates an amine-
modified UTP into the probe template. The purified RNA is then
incubated with an amine-reactive Alexa Fluor 488 dye (e.g. the
succinimidyl ester of Alexa Fluor 488 carboxylic acid) which binds
and reacts with the modified UTP. The conjugated probe is then
purified, quantified, denatured, and incubated with cells. Before
hybridization, cells were fixed and permeabilized as described
above, and then prehybridized in 50% PBST/50% hybridization
buffer (50% formamide, 5X SSC, 1 mM phosphate buffer,
pH 7.4, 1X Denhardt’s solution, and 160 ng/ml of denatured
salmon sperm DNA) at room temperature for 10 min with gentle
rocking. After two washes with fresh hybridization buffer for
30 min at 42uC, the probe was added to the hybridization buffer
and incubated with the cells for 16 h at 42uC. After hybridization,
cells were processed for immunofluorescence as described above.
Probes were visualized using the LSM 700 laser scanning confocal
Axio Observer. Z1 microscope (Zeiss), equipped with a software
ZEN 2009 for image acquisition and analysis. Images were
acquired through the following settings: 63X oil objective (zoom
1.0), 0.06 um for pixel size, and 1.00 airy units (AU) as Pinhole.
Immunoprecipitation, Quantitative RT-PCR and
Actinomycin D Experiments
For immunoprecipitation, cells were collected and lysed at 4uC
with a lysis buffer (50 mM Tris-HCl, pH 7.4; 0.5% NP-40;
150 mM NaCl; 1 mM MgCl2; 0.25 mM phenylmethanesulfonyl-
fluoride; 0.5 mM DTT) containing a cocktail of protease inhibitors
(Roche, Laval, QC, Canada) and 40 U/ml RNase Inhibitor
(Invitrogen). The extract was then incubated with protein A
Sepharose CL-4B beads (GE Healthcare Life Sciences, Baie-
d’Urfe ´, QC, Canada) conjugated with the appropriate antibody.
Following three washes with lysis buffer, the beads were
resuspended with an equal volume of washing buffer. Five percent
of the suspension was used for immunoblot analysis of the
immunoprecipitated proteins, and the remainder was used for
RNA isolation. Briefly, following digestion with proteinase K,
RNA was extracted with phenol/CHCl3 and precipitated with
isopropanol in the presence of glycogen. RNA was resuspended in
water and analyzed by qRT-PCR.
RT-PCR reactions were performed using the Quantitect
Reverse Transcriptase kit (Qiagen). Each reaction contained 2 ml
of RNA (isolated using the RNeasy Plus Mini Kit; Qiagen) at
100 ng/ml, 10 ml of RNase-free water, 2 ml of genomic DNA
Wipeout Buffer 7X, 4 ml of Quantiscript RT Buffer 5X, 1 mlo f
RT Primer Mix and 1 ml of Quantiscript Reverse Transcriptase.
Real-time PCR reactions were prepared using the Power
SYBRH Green PCR Master mix (Applied Biosystems, Streetsville,
ON, Canada) in a total volume of 25 ml: 12.5 ml of PCR Master
Mix, 0.67 ml of forward primer at 3.75 mM, 0.67 ml of reverse
primer at 3.75 mM, 9.2 ml of deionized (Milli-Q grade) water and
2 ml of RT-PCR. Reactions were run and data then analyzed
using the MX3000 Real-Time PCR system (Applied Biosystems)
with a 4-stage program: (1) 2 min at 50uC, (2) 10 min at 95uC, (3)
40 cycles of a 2-step reaction: 95uC615 s and 55uC660 s, and (4)
a 3-step reaction: 95uC 615 s, 60uC 620 s and 95uC 615 s.
To prepare templates for the p21 mRNA, the oligonucleotide
pair used was: 59-GACTTTGTCACCGAGACACC-39 (forward),
and 59-GACAGGTCCACATGGTCTTC-39 (reverse). For pre-
paring templates corresponding to the p27 mRNA, the oligonu-
cleotide pair used was: 59-AAGAGTTAACCCGGGACTTG-39
(forward), and 59-CCACTCGTACTTGCCCTCTA-39 (reverse).
For preparing templates corresponding to the GAPDH mRNA, the
oligonucleotide pair used was: 59-ACGACCACTTTGTCAAG-
CTC-39 (forward), and 59-GTTGCTGTAGCCAAATTCGT-39
(reverse).
For actinomycin D experiments, transcription was blocked
using 5 mg/mL actinomycin D. RNA was isolated and analyzed as
described above.
Annexin V-Fluorescein Isothiocyanate/Propidium Iodide
Assay and FACS Analysis
At the end of the experimental treatment, both adherent and
detached cells were harvested. Cells were washed with ice-cold
PBS, then pelleted again at 1500 rpm for 10 min at 4uC, and
resuspended in ice-cold binding buffer (10 mM HEPES/NaOH,
pH 7.4, 140 mM NaCl, 2.5 mM CaCl2). Cells were subsequently
stained with annexin V-fluorescein isothiocyanate (FITC) and
propidium iodide (PI) for 15 min in the dark. A total of 5610
4 cells
were counted, and dead cells were examined by flow cytometry.
For FACS analysis, collected cells were fixed with 3% parafor-
maldehyde, washed with PBS, and stained with 49,6-diamidino-2-
phenylindole (DAPI) (1 mg/mL) and analyzed by flow cytometry.
Clonogenic Survival Assay
Cells were plated in duplicate and incubated for 24 h. Following
treatment, cells were washed with PBS, trypsinized, counted,
replated in 6-well plates at 10
3 cells/well in the absence of drug,
and incubated for 10 d. Before colony counting, cells were washed
with PBS, stained (0.1% (w/v) crystal violet in a 0.0037% (v/v)
formaldehyde solution in PBS), rinsed with deionized H2O, and
dried. Populations .50 cells were counted as one surviving colony.
Supporting Information
Figure S1 Time course analysis of SG formation and
p21 expression during bortezomib treatment. (A) HeLa
cells were treated with 2 mM bortezomib for the indicated period
and then processed for immunofluorescence. SG were visualized
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anti-p21 antibodies. The percentage of cells harboring SG from
five different fields and three different experiments containing a
total of 1000 cells is indicated on the bottom of each merge
pictures. (B) HeLa cells were treated with 2 mM bortezomib for the
indicated period then collected for western blot analysis. Proteins
were extracted and analyzed for the expression of p21 and as a
loading control G3BP1, using the corresponding antibodies. The
amount of p21 was determined by quantitation of the signals on
films by densitometry using Adobe Photoshop software and
expressed as percentage relative to the amounts of G3BP1. (C)
qRT-PCR of p21 mRNA. Following treatment with 2 mM
bortezomib for the indicated period, cells were collected and total
RNA content was then isolated. The amount of p21 was
quantified by real time-PCR relative to GAPDH mRNA using
the DDCt method. Results are expressed as the mean 6 SEM
(error bars) of triplicate measurements. (D-E) Quantification of
p21 immunofluorescence signal in nuclei versus the cytoplasm of
cells treated with bortezomib for either, 10 h (D) or 16 h (E), using
Adobe Photoshop software.
(TIF)
Figure S2 Bortezomib upregulates p21 mRNA expres-
sion in different cancer cells. (A-B) Calu-I and MCF-7 cells
were treated with bortezomib and processed for immunofluores-
cence (A), or lysed, and their protein extracts were analyzed for the
levels of p21 and tubulin (B), as described in the legend to Figure 1.
(TIF)
Figure S3 Expression profile of proteasome substrates
during bortezomib treatment. GFPu-expressing 293 cells (A)
and HeLa (B) were treated with 2 mM bortezomib for the indicated
time. Proteins were extracted and analyzed for the expression of
GFPu (A) and p27 (B), using the corresponding antibodies. G3BP1
was used as a loading control. The amounts of GFPu and p27
were determined by quantitation of the signals on films by
densitometry using Adobe Photoshop software and expressed as a
percentage relative to the amounts of G3BP1.
(TIF)
Figure S4 Prolonged treatment with bortezomib induc-
es a redistribution of the p21 mRNA in the cytoplasm
and nuclei. (A-B) HeLa cells were treated with 2 mM bortezomib
for the indicated periods. SG were visualized with anti-FMRP and
anti-G3BP1 antibodies, and p21 mRNA was detected by FISH.
The percentage of SG is indicated. The percentage of cells
harboring SG positive for p21 mRNA is also indicated. Shown are
typical results from five different fields and three different
experiments containing a total of more than 1000 cells. (B)
Densitometry quantification of p21 mRNA FISH signal in SG
versus the cytoplasm was done with Adobe Photoshop software as
described in Figure 2B. (C) HeLa cells were treated with 2 mM
bortezomib for 10 h. SG were visualized with anti-CUGBP1
antibodies. DAPI depicts nuclei.
(TIF)
Figure S5 HRI depletion prevents bortezomib-induced
SG formation and p21 mRNA accumulation. (A-C) HeLa
cells were treated with HRI-specific siRNA or with control siRNA,
and then incubated with bortezomib (2 mM) for 4 h. (A-B) Cells
were harvested and their RNA and proteins content isolated. (A)
Levels of p21 mRNA was measured by qRT-PCR and
standardized against GAPDH mRNA as described in the legend
of Figure 2. (B) Depletion of HRI was assessed by western blot
using anti-HRI antibodies. (C) Cells were processed for immuno-
fluorescence to detect SG using anti-G3BP and anti-FMRP
antibodies. The percentage of cells harboring SG from five
different fields and three different experiments containing a total of
1000 cells is indicated.
(TIF)
Figure S6 CUGBP1 depletion does not affect the steady-
state level of the p21 mRNA in SG-free conditions tested.
(A-C) Seventy-two hours following transfection with CUGBP1, or
control siRNAs, cells were left untreated (A), or were treated with 1
mM staurosporine (B) or 2 mM bortezomib (C) for 4 h, as indicated.
Total RNA was isolated and the level of p21 mRNA expression was
determined by qRT-PCR, standardized against GAPDH mRNA,
and quantified as described in Figure 2. Results are expressed as a
percentage of the mRNA levels present in mock-depleted cells. (D)
Staurosporine treatment does not induce SG. HeLa cells were
treated with bortezomib (2 mM, 4 h) or Staurosporine (1 mM, 4 h)
then processed to visualize SG using anti-FMRP and anti-G3BP1
antibodies as described above. DAPI depicts nuclei. The percentage
of SG is indicated at the top of each panel.
(TIF)
Figure S7 CUGBP1 depletion does not affect GAPDH
mRNA localization in SG. HeLa cells were treated with non-
specific, or with CUGBP1-directed siRNA, incubated with
bortezomib (2 mM) for 4 h and processed for FISH to detect
GAPDH mRNA coupled with immunofluorescence to visualize
SG using antibodies against CUGBP1 and G3BP1 proteins.
Immunofluorescence using anti-CUGBP1 antibodies is used to
monitor CUGBP1 depletion. The percentage of SG is indicated at
the bottom of the right panels. The percentage of cells harboring
SG positives for GAPDH mRNA is also indicated. Those
percentages are representative of typical results from three
different experiments counting more than 1000 cells.
(TIF)
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